BLRX:NSD-BioLineRx Ltd (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 1.27

Change

0.00 (0.00)%

Market Cap

USD 0.07B

Volume

0.12M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

BioLineRx Ltd (BLRX) Stock Analysis:
Based on the BioLineRx Ltd stock forecasts from 0 analysts, the average analyst target price for BioLineRx Ltd is not available over the next 12 months. BioLineRx Ltd’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of BioLineRx Ltd is Neutral, which is based on 3 positive signals and 3 negative signals. At the last closing, BioLineRx Ltd’s stock price was USD 1.27. BioLineRx Ltd’s stock price has changed by +5.83% over the past week, -12.41% over the past month and -59.03% over the last year.

About

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the trea ...Read More

Company Website : https://www.biolinerx.com

Address : Modi?in Technology Park, Hevel Modi'in, Israel, 7177871

Employees : 38

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 1.44

52 Week High : 3.62

Short Ratio : 1.99

52 Week Low : 1.01

Shorted Shares : 364,954

200 Day Moving Average : 2.18

Shorted Shares Previous Month : 403,343

50 Day Moving Average : 1.47

Short Percentage : 0.45%

Shares Held by Institutions : 7.20%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-21 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
REGN Regeneron Pharmaceuticals Inc

N/A

 USD72.19B 9.35 7.18
VRTX Vertex Pharmaceuticals Incorpo..

N/A

 USD65.33B 26.96 18.70
MRNA Moderna Inc

N/A

 USD57.03B 4.22 2.75
ALXN Alexion Pharmaceuticals Inc

N/A

 USD40.34B 59.23 42.56
BNTX BioNTech SE

N/A

 USD38.17B 3.01 1.65
RPRX Royalty Pharma plc

N/A

 USD26.82B 29.06 15.54
SGEN Seagen Inc

N/A

 USD25.70B 55.02 44.86
IMMU Immunomedics, Inc

N/A

 USD20.31B N/A N/A
GMAB Genmab A/S

N/A

 USD19.45B 58.02 5.06
ARGX argenx SE

N/A

 USD17.61B N/A N/A

ETFs Containing BLRX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -37.75% 62% D- 33% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -37.75% 62% D- 33% F
Trailing 12 Months  
Capital Gain -59.03% 57% F 27% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -59.03% 57% F 27% F
Trailing 5 Years  
Capital Gain 44.25% 78% C+ 69% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 44.25% 78% C+ 66% D
Average Annual (5 Year Horizon)  
Capital Gain 72.80% 86% B 92% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 72.80% 86% B 92% A-
Risk Return Profile  
Volatility (Standard Deviation) 148.31% 16% F 8% F
Risk Adjusted Return 49.08% 86% B 77% C+
Market Capitalization 0.07B 34% F 22% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 0.84 75% C 82% B-
Price / Cash Flow Ratio -2.77 53% F 65% D
EV/EBITDA 0.06 91% A- 97% A+
Management Effectiveness  
Return on Equity -34.03% 74% C 30% F
Return on Invested Capital -50.20% 54% F 20% F
Return on Assets -20.05% 65% D 20% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 1.99 75% C 64% D
Short Percent 0.45% 91% A- 82% B-
Beta 1.44 46% F 28% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date
New Post

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.